GC Cell begins tech transfer of Immuncell-LC to Indonesia’s Kalbe Farma
GC Cell said Wednesday that it has officially begun the technology transfer process for its immunotherapy, Immuncell-LC, in collaboration with PT Bifarma Adiluhung, the Indonesian subsidiary of Southeast Asia’s largest pharmaceutical company, PT Kalbe Farma Tbk.
The technology transfer follows a licensing agreement signed in September and represents a key step toward the commercialization of Immuncell-LC in Indonesia.
A GC Cell official said the project, launched this month, is expected to take approximately six months to complete. The company is currently conducting intensive technology transfer sessions at its headquarters, focusing on manufacturing and quality control (QC) processes. Bifarma's production and quality management teams are participating to ensure readiness for local production and commercialization.
As Kalbe Farma's cell therapy subsidiary, Bifarma is equipped with a robust local infrastructure for the production, sales, and logistics of cell therapies. GC Cell expects this partnership to enable the swift commercialization of Immuncell-LC in Indonesia after the transfer process is completed.
“This marks our first technology transfer under the licensing agreement and a significant milestone for Immuncell-LC’s entry into global markets,” said the GC Cell official. “As the first cancer immunotherapy to be commercialized in Indonesia, we are fully committed to ensuring the success of local production and commercialization through close collaboration with Bifarma.”
GC Cell anticipates milestone revenues upon completing the technology transfer, though the amount remains undisclosed, and plans to generate royalty income from subsequent commercialization. Additionally, the company will host a global symposium in Indonesia in January next year, bringing together healthcare professionals and key opinion leaders (KOLs) to highlight the efficacy and safety of Immuncell-LC, foster academic exchanges, and strengthen its global profile.